Pyxis Oncology, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Pyxis Oncology issued $49,999,990.30 of common stock at $2.551/share and warrants to purchase 19,600,153 shares at $3.289/share to unnamed institutional investors (Wells Fargo Securities as placement agent, dated June 30, 2026, closed July 2, 2026). Warrants exercisable upon MICVO clinical data disclosure or October 1, 2026. Company granted mandatory registration rights with October 2, 2026 filing deadline and 75-day effectiveness requirement, with 1.0% monthly liquidated damages for registration failures.
Why this rating
Financing equals 77.6% of $64.4M market cap—transformational capital infusion. Registration rights and warrant overhang create complexity but critical for small biotech runway.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.